These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 23733001)

  • 41. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics.
    Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fluorescence in situ hybridization analysis of immunoglobulin heavy chain translocations in plasma cell myeloma using intact paraffin sections and simultaneous CD138 immunofluorescence.
    Cook JR; Hartke M; Pettay J; Tubbs RR
    J Mol Diagn; 2006 Sep; 8(4):459-65. PubMed ID: 16931586
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.
    Grzasko N; Hajek R; Hus M; Chocholska S; Morawska M; Giannopoulos K; Czarnocki K; Druzd-Sitek A; Pienkowska-Grela B; Rygier J; Usnarska-Zubkiewicz L; Dytfeld D; Kubicki T; Jurczyszyn A; Korpysz M; Dmoszynska A
    Leuk Lymphoma; 2017 Sep; 58(9):1-15. PubMed ID: 28092996
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular breakpoints of t(11;14)(q13;q32) in multiple myeloma.
    Meeus P; Stul MS; Mecucci C; Cassiman JJ; Van den Berghe H
    Cancer Genet Cytogenet; 1995 Aug; 83(1):25-7. PubMed ID: 7656199
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial.
    Giralt S; Costa LJ; Maloney D; Krishnan A; Fei M; Antin JH; Brunstein C; Geller N; Goodman S; Hari P; Logan B; Lowsky R; Qazilbash MH; Sahebi F; Somlo G; Rowley S; Vogl DT; Vesole DH; Pasquini M; Stadtmauer E
    Biol Blood Marrow Transplant; 2020 Apr; 26(4):798-804. PubMed ID: 31756536
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
    Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
    [TBL] [Abstract][Full Text] [Related]  

  • 47. t(11;14) multiple myeloma: a subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome.
    An G; Xu Y; Shi L; Zou D; Deng S; Sui W; Xie Z; Hao M; Chang H; Qiu L
    Leuk Res; 2013 Oct; 37(10):1251-7. PubMed ID: 23927993
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.
    Kröger N; Badbaran A; Zabelina T; Ayuk F; Wolschke C; Alchalby H; Klyuchnikov E; Atanackovic D; Schilling G; Hansen T; Schwarz S; Heinzelmann M; Zeschke S; Bacher U; Stübig T; Fehse B; Zander AR
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):398-404. PubMed ID: 23078786
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: An observational multi-center retrospective study.
    Cohen YC; Saranga A; Gatt ME; Lavi N; Ganzel C; Magen H; Avivi I; Tadmor T; Suriu C; Jarchowsky Dolberg O; Papushado A; Trestman S; Ram R
    Am J Hematol; 2018 Jun; 93(6):810-815. PubMed ID: 29603773
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants.
    Avet-Loiseau H; Garand R; Lodé L; Harousseau JL; Bataille R;
    Blood; 2003 Feb; 101(4):1570-1. PubMed ID: 12393502
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cyclin D1 expression in patients with multiple myeloma.
    Troussard X; Avet-Loiseau H; Macro M; Mellerin MP; Malet M; Roussel M; Sola B
    Hematol J; 2000; 1(3):181-5. PubMed ID: 11920187
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
    Veltri LW; Milton DR; Delgado R; Shah N; Patel K; Nieto Y; Kebriaei P; Popat UR; Parmar S; Oran B; Ciurea S; Hosing C; Lee HC; Manasanch E; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
    Cancer; 2017 Sep; 123(18):3568-3575. PubMed ID: 28513828
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes.
    Hu B; Thall P; Milton DR; Sasaki K; Bashir Q; Shah N; Patel K; Popat U; Hosing C; Nieto Y; Lin P; Delgado R; Jorgensen J; Manasanch E; Weber D; Thomas S; Orlowski RZ; Champlin R; Qazilbash MH
    Leuk Lymphoma; 2019 Feb; 60(2):442-452. PubMed ID: 30032678
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation-study on behalf of CMWP of the EBMT.
    Drozd-Sokołowska J; Gras L; Zinger N; Snowden JA; Arat M; Basak G; Pouli A; Crawley C; Wilson KMO; Tilly H; Byrne J; Bulabois CE; Passweg J; Ozkurt ZN; Schroyens W; Lioure B; Colorado Araujo M; Poiré X; Van Gorkom G; Gurman G; de Wreede LC; Hayden PJ; Beksac M; Schönland SO; Yakoub-Agha I
    Bone Marrow Transplant; 2022 Apr; 57(4):633-640. PubMed ID: 35169284
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses.
    Fabris S; Agnelli L; Mattioli M; Baldini L; Ronchetti D; Morabito F; Verdelli D; Nobili L; Intini D; Callea V; Stelitano C; Lombardi L; Neri A
    Genes Chromosomes Cancer; 2005 Feb; 42(2):117-27. PubMed ID: 15543617
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years.
    Bashir Q; Chamoun K; Milton DR; Khan M; Ahmed S; Mehta R; Popat UR; Kebriaei P; Nieto Y; Oran B; Ciurea SO; Hosing C; Khouri I; Patel K; Manasanch EE; Lee HC; Orlowski RZ; Champlin RE; Qazilbash MH
    Leuk Lymphoma; 2019 Dec; 60(14):3536-3543. PubMed ID: 31282244
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical and biologic implications of recurrent genomic aberrations in myeloma.
    Fonseca R; Blood E; Rue M; Harrington D; Oken MM; Kyle RA; Dewald GW; Van Ness B; Van Wier SA; Henderson KJ; Bailey RJ; Greipp PR
    Blood; 2003 Jun; 101(11):4569-75. PubMed ID: 12576322
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis.
    El-Ghammaz AM; Abdelwahed E
    Ann Hematol; 2016 Aug; 95(8):1315-21. PubMed ID: 27184486
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genomic aberrations and survival of patients with light-chain-only multiple myeloma undergoing autologous stem cell transplantation.
    Jiang N; Qi C; Trieu Y; Reece D; Chang H
    Biol Blood Marrow Transplant; 2011 Dec; 17(12):1790-5. PubMed ID: 21658460
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Analysis of the efficacy and prognosis on first-line autologous hematopoietic stem cell transplantation of patients with multiple myeloma].
    Zou DH; Sui WW; Yi SH; An G; Xu Y; Li ZJ; Li CW; Qi JY; Zhao YZ; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):299-303. PubMed ID: 23668200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.